While both OA and RA are characterized by increased amounts of metalloproteases in synovium and cartilage, the synovial involvement is far more pronounced in RA. Thus the pathway of joint destruction in RA is thought to overlap the events causing OA, but to be broader in scope and to engage more members of the cytokine network. 3, 4 The aetiology of OA is thought to involve precipitating events ranging from crystal deposition, joint neuropathy, sub-chondral sclerosis, mechanical defects, metabolic 56 The appearance of these antibodies occurs after articular cartilage damage has begun. The loss of cartilage may be accelerated by the deposition of immune complexes in the superficial layers of the cartilage, which favours invasion of the pannus. 57 Neuropeptides may play a role in the modulation of the inflammatory response. 58 Substance P, a peptide located in peripheral nerves, has been shown to induce the production of cytokines (IL-1, TNFz and IL-6) by mononuclear cells 59 In cartilage, TNF(x appears to induce many effects analogous to those generated by IL-1, although the former is generally less potent in its effect than either form of IL-1. 93 Although the effect of TNF0t on chondrocytes has been less well Studied than that of IL-1, it is clear that TNF, like IL-1, can stimulate the production of proteolytic enzymes such as collagenase, stromelysin, elastase and PA, as well as prostaglandins E and IL-6. TNFot also has, however, no effect on TIMP production by articular chondrocytes. TNFx also modulates the synthesis of cartilage matrix and, like IL-1, suppresses aggregating proteoglycan synthesis 94 and selectively decreases the production of cartilage type and type II collagens. It suppresses the expression of type II collagen, but increases type and III collagen gene expression. 95 In contrast to its detrimental role of inhibiting proteoglycan synthesis, IL-6 does not appear to influence the production of the metalloproteases, either alone or in combination with IL-1. 96 16, 162 The IL-1 genes are under specific transcriptional control which is influenced by cell type and the inducing agent, and modulated by other cytokines. The differential expression of IL-lot and IL-I may be explained in part by the marked structural differences between the two promoters. 163 The biological properties of IL-1 are similar to and overlap those of TNF. In some situations, potentiation or synergism between IL-1 and TNF occurs, an effect that seems to derive from signal transducing molecules rather than upregulation of receptors, since IL-1 down-regulates TNF receptors. 164, 165 As reviewed by Fenton, 62 9 One IL-6 action, fever, is blocked by cyclooxygenase inhibitors indirectly through increased release of arachidonic acid. 13 Soluble p80R for IL-6 enhances activity. 181, 82 Cytokine reducing effects of anti-arthritic drugs
The scope, target mechanisms and effectiveness of anti-rheumatic drugs in the pre-cytokine era were thoroughly reviewed by Bonta and colleagues. 18 The use of cyclooxygenase inhibitors to inhibit the production of prostaglandins has been a major element in the clinical management of arthritis for about 100 years, while our understanding of the role of prostaglandins in inflammation has been developed over the past 20 years.
Non-steroidal anti-inflammatory drugs: The proand anti-inflammatory action of PGE has been recognized for a number of years. 8 
